Lung Disease Clinical Trials 2023

What are the top hospitals conducting lung disease research?

When it comes to advancing treatments for lung diseases, several top hospitals are leading the way. In Boston, Massachusetts General Hospital stands out with nine ongoing clinical trials dedicated to various lung conditions. With a rich history of 22 completed studies in this field since their first recorded trial back in 1994, they have been at the forefront of lung disease research for decades. Moving westward to Rochester, Minnesota, the renowned Mayo Clinic is making significant contributions as well. Currently conducting five active lung disease trials and having completed 30 previous studies since their inaugural trial in 2006, this institution continues to push boundaries in understanding and treating respiratory ailments.

Meanwhile, on the east coast in Philadelphia, researchers at the University of Pennsylvania, Minnesota, the renowned Mayo Clinic is making significant contributions as well. Currently conducting five active lung disease trials and having completed 30 previous studies since their inaugural trial in 2006, this institution continues to push boundaries in understanding and treating respiratory ailments.

Meanwhile, on the east coast in Philadelphia, researchers at the University of Pennsylvania are actively engaged in five clinical trials focused on lung diseases. Since embarking on their first recorded trial in partnership with Massachusetts General Hospital back in 1994, they have amassed a total of 16 studies aimed at improving outcomes for patients suffering from respiratory disorders.

In another corner of Boston's prestigious medical community lies Dana-Farber Cancer Institute. Although traditionally recognized for its cancer research expertise, this institute has recently ventured into exploring treatment options for lung diseases as well. With four active clinical trials currently underway and plans underway to expand these efforts following its first-ever recorded lung disease trial earlier this year (2021), Dana-Farber brings fresh perspectives and innovation to this critical area of study.

Finally heading down south but no less committed is University of Alabama at Birmingham located right within Birmingham town . This esteemed institution is actively involved in four ongoing clinical trials addressing various types of lung diseases while having previously conducted an impressive tally thirty-three investigations from establishing debut case records dating all way back until '98; such extensive experience places them among top contributors nationwide when it comes towards vital understanding as well overcoming challenges related towards debilitating respiratory disorders

These hospitals serve as beacons of hope amidst the challenging landscape posed by lung diseases that affect countless individuals across the nation. Through their tireless efforts and pioneering research, they strive to alleviate suffering, improve quality of life, and ultimately find a cure for these conditions.

Which are the best cities for lung disease clinical trials?

When it comes to lung disease clinical trials, several cities stand out for their active research and development. Boston, Massachusetts leads the way with 31 ongoing trials exploring treatments like Ralinepag, Cohort A: Belumosudil + Standard of Care Medications, and epetraborole + OBR. New York, New York follows closely behind with 25 active studies focused on innovative approaches such as Ralinepag, BLU-451, and BLU-945. Los Angeles, California. New York, New York follows closely behind with 25 active studies focused on innovative approaches such as Ralinepag, BLU-451, and BLU-945. Los Angeles, California also plays a significant role in advancing lung disease treatment with 18 ongoing trials investigating options like Ralinepag and MK-2225. These cities are at the forefront of groundbreaking research that offers hope for improved outcomes in lung disease care.

Which are the top treatments for lung disease being explored in clinical trials?

Cutting-edge research in the field of lung disease has led to the exploration of several promising treatments in clinical trials. Notably, ralinepag showcases its potential with two active trials and three all-time lung disease trials since its introduction in 2018. Abatacept is also gaining attention, currently participating in two ongoing studies while accumulating four all-time lung disease trials since its listing in 2017. Another contender, nintedanib, demonstrates promise with two active and thirteen all-time lung disease trials since it was first listed back in 2017. Finally, MRI at baseline and over time emerges as an innovative approach with two active trials despite only one all-time trial recorded since 2007. These advancements bring hope for improved treatment options and outcomes for individuals affected by various forms of lung diseases worldwide.

What are the most recent clinical trials for lung disease?

Recent clinical trials have brought promising developments for individuals grappling with lung disease. Among these advancements are efzofitimod 450 mg, a Phase 2 trial that demonstrates potential benefits in the management of this condition. Similarly, another Phase 2 trial explores the efficacy of mycophenolate mofetil as a treatment option. Additionally, a Phase 4 study evaluates the effectiveness of combining nintedanib with standard care for lung disease patients. Moreover, ongoing research investigates vixarelimab's impact on this respiratory ailment in its Phase 2 cohort study known as DBT: Cohort 1. Lastly, there is phase two testing underway to examine the effects of fisetin group on lung disease outcomes. These innovative trials offer hope and progress for those affected by lung disease.

What lung disease clinical trials were recently completed?

Several recent clinical trials have concluded, focusing on advancing treatments for various lung diseases. In September 2021, Novartis Pharmaceuticals completed a trial investigating the efficacy of CSJ117. Additionally, Eisai Inc. finalized a trial in December 2020 assessing the effectiveness of Lemborexant 10 mg. Another notable study conducted by Verona Pharma plc investigated Ensifentrine and was completed in September 2020. While these trials offer valuable insights into potential treatments for lung diseases, ongoing research is crucial to further improve outcomes and provide hope for patients battling respiratory conditions.